Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Stopped early · Phase 2

Conditions studied: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer

In brief

This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key facts

Study ID

NCT00459108

Run by

National Cancer Institute (NCI)

People needed

25

Starts

2007-04-01

Expected to finish

2011-04-01

Last updated by the study team

2018-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Southern California, Norris — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.